Ozanimod as a novel oral small molecule therapy for the treatment of Crohn's disease: The YELLOWSTONE clinical trial program
Open Access
- 5 October 2022
- journal article
- research article
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 122, 106958
Abstract
No abstract availableKeywords
Funding Information
- Bristol-Myers Squibb
This publication has 35 references indexed in Scilit:
- Ozanimod Induction and Maintenance Treatment for Ulcerative ColitisNew England Journal of Medicine, 2016
- Ozanimod (RPC1063) is a potent sphingosine‐1‐phosphate receptor‐1 (S1P1) and receptor‐5 (S1P5) agonist with autoimmune disease‐modifying activityBritish Journal of Pharmacology, 2016
- Development and validation of a histological index for UCGut, 2015
- Sphingosine 1-Phosphate Receptor Modulators in Multiple SclerosisCNS Drugs, 2015
- Systematic review: Histological remission in inflammatory bowel disease. Is ‘complete’ remission the new treatment paradigm? An IOIBD initiativeJournal of Crohn's and Colitis, 2014
- Central endoscopy reads in inflammatory bowel disease clinical trials: The role of the imaging core labGastroenterology Report, 2014
- A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple SclerosisNew England Journal of Medicine, 2010
- Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple SclerosisNew England Journal of Medicine, 2010
- Finding a way out: lymphocyte egress from lymphoid organsNature Immunology, 2007
- Adalimumab Induction Therapy for Crohn Disease Previously Treated with InfliximabAnnals of Internal Medicine, 2007